Clinical Study
Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
Table 3
Number of patients who experienced a grade 3 or 4 toxicity.
| NCI-CTCAE grade 3-4 toxicity | Grade 3 | Grade 4 |
| Hematological toxicity | | | Anemia | 3 (7.0%) | 1 (2.3%) | Leucopenia | 1 (2.3%) | 2 (4.7%) | Neutropenia | 5 (11.6%) | 3 (7.0%) | Thrombocytopenia | 1 (2.3%) | 0 (0.0%) |
| Nonhematological toxicity | | | Fatigue | 9 (20.5%) | 0 (0.0%) | Nausea | 2 (4.5%) | 0 (0.0%) | Diarrhea | 5 (11.4%) | 1 (2.3%) | Vomiting | 3 (6.8%) | 0 (0.0%) | Anorexia | 2 (4.5%) | 0 (0.0%) | Mucositis/stomatitis | 2 (4.5%) | 0 (0.0%) | Dehydration | 2 (4.5%) | 0 (0.0%) | Febrile neutropenia | 1 (2.3%) | 0 (0.0%) | Infection | 0 (0.0%) | 1 (2.3%) | Rash | 1 (2.3%) | 0 (0.0%) | Biochemistry | | | ALAT increase | 4 (9.5%) | 0 (0.0%) | Hyperbilirubinemia | 2 (4.8%) | 0 (0.0%) | Hypokalemia | 2 (4.8%) | 0 (0.0%) | Alkaline phosphatase | 1 (2.4%) | 0 (0.0%) | Hyponatremia | 1 (2.4%) | 0 (0.0%) |
|
|
Abbreviations: NCI-CTCAE: National Cancer Institute-Common Terminology Criteria for Adverse Events; ALAT: alanine aminotransferase.
|